RVNC - Revance Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.00
-0.50 (-3.45%)
At close: 4:00PM EDT

14.00 0.00 (0.00%)
After hours: 4:12PM EDT

Stock chart is not supported by your current browser
Previous Close14.50
Open14.50
Bid13.99 x 2200
Ask14.01 x 2200
Day's Range13.48 - 14.56
52 Week Range9.88 - 26.89
Volume559,635
Avg. Volume405,637
Market Cap617.435M
Beta (3Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire

    Revance to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference

    Revance Therapeutics, Inc. (RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Morgan Stanley 17th Annual Global Healthcare Conference, in New York, NY. President and Chief Executive Officer, Dan Browne, is scheduled to take part in a fireside chat on Tuesday, September 10 at 4:40 p.m. ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com.

  • Business Wire

    Revance to Participate in the Wells Fargo 14th Annual Healthcare Conference

    Revance Therapeutics, Inc. , a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Wells Fargo 14th Annual Healthcare Conference, in Boston, MA.

  • Business Wire

    Revance Reports Second Quarter 2019 Financial Results, Provides Corporate Update

    - Conference call and webcast today at 4:30 p.m. ET -

  • ACCESSWIRE

    Revance Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 5, 2019 / Revance Therapeutics, Inc. (NASDAQ: RVNC ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 5, 2019 at 4:30 ...

  • Business Wire

    Revance Adds Iconic Brand Builder Jill Beraud to Board of Directors

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing a new category of high-performance neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the appointment of Jill Beraud to the company’s Board of Directors. Ms. Beraud brings more than 25 years’ experience building luxury, fashion, beauty, and consumer brands. Ms. Beraud will also chair a newly-formed Revance Brand Strategy Committee focused on establishing the company’s innovative neuromodulator, DaxibotulinumtoxinA for Injection (DAXI), in the minds of consumers.

  • Business Wire

    Revance to Participate in the Goldman Sachs 40th Annual Global Healthcare Conference

    Revance Therapeutics, Inc. , a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the Goldman Sachs 40th Annual Global Healthcare Conference in Rancho Palos Verdes, CA.

  • Business Wire

    Revance to Participate in the RBC Capital Markets 2019 Healthcare Conference

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the RBC Capital Markets 2019 Healthcare Conference in New York, NY. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. Revance Therapeutics is a biotechnology company focused on developing transformative neuromodulators to address a broad spectrum of aesthetic and therapeutic conditions.

  • Business Wire

    Revance Reports First Quarter 2019 Financial Results and Provides Corporate Update

    - Conference call and webcast today at 4:30 p.m. ET -

  • Business Wire

    Revance to Release First Quarter 2019 Financial Results on Wednesday, May 8, 2019

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will release first quarter 2018 financial results on Wednesday, May 8, 2019 after the close of market. DAXI has the potential to be the first long-acting neuromodulator.

  • Business Wire

    Revance Appoints Former Allergan Marketing Veteran Taryn Conway as Vice President of Marketing

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced a pivotal addition to its leadership team with the appointment of Taryn Conway as Vice President, Marketing, effective April 8, 2019. As the company transitions from clinical-stage development to commercialization, Ms. Conway will be an integral architect of product launch strategies and implementation, reporting to Head of Commercial - Aesthetics and Therapeutics, Dustin Sjuts. “We’re thrilled that Taryn will be leading our marketing efforts as we approach the anticipated launch of our first-in-class, long-lasting neuromodulator, DaxibotulinumtoxinA for Injection (DAXI),” said Dustin Sjuts, Head of Commercial - Aesthetics and Therapeutics, for Revance.

  • Business Wire

    SAKURA 3 Trial Results Presented on Podium at World’s Largest Medical Aesthetic Conference

    – Unprecedented clinical results for DaxibotulinumtoxinA for Injection , Revance’s long-acting neuromodulator, were highlighted at the 17th Aesthetics & Anti-Aging Medica

  • Business Wire

    Revance to Participate in the Needham Healthcare Conference

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in the Needham Healthcare Conference in New York, NY. Chief Financial Officer, Tobin Schilke, is scheduled to present on Tuesday, April 9 at 12:00pm ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com.

  • GlobeNewswire

    New Research: Key Drivers of Growth for Fresh Del Monte Produce, Baker Hughes, a GE company, HollyFrontier, Glaukos, HCI Group, and Revance Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire

    Revance to Participate in Upcoming Investor Conferences

    Revance Therapeutics, Inc. , a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.

  • Business Wire

    Revance Releases Fourth Quarter and Full Year 2018 Results

    -Successful 2018: Positive SAKURA 3 topline data, Fosun and Mylan partnerships signed-

  • Business Wire

    Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019

    Conference Call Scheduled for Tuesday, February 26, 2019 at 4:30pm ET

  • GlobeNewswire

    CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors

    CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the appointment of Phyllis Gardner, M.D., to its Board of Directors and to the Board’s Audit Committee. “Dr. Gardner’s very broad and deep expertise in medicine, biotechnology, and corporate investing and governance is an ideal skill set for the CohBar Board as we strategically advance our portfolio and pipeline of mitochondrial peptides and disease targets,” said Albion Fitzgerald, Chairman of the Board.

  • GlobeNewswire

    Investor Expectations to Drive Momentum within International Paper, Gray Television, Nielsen Holdings Plc, e.l.f. Beauty, NIC, and Revance Therapeutics — Discovering Underlying Factors of Influence

    NEW YORK, Jan. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire

    Revance Announces Closing of Public Offering of Common Stock

    Gross Proceeds of Offering Total 115.0 Million

  • Business Wire

    Revance Announces Pricing of Public Offering of Common Stock

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced the pricing of an underwritten public offering of 5,882,353 shares of its common stock at a price to the public of $17.00 per share. Revance has granted the underwriters a 30-day option to purchase up to an aggregate of additional 882,352 shares from the Company. The gross proceeds to the Company from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be approximately $100 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.

  • Business Wire

    Revance Announces Proposed Public Offering of Common Stock

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public offering in which it will issue and sell approximately $100 million of shares of its common stock. Revance expects that the underwriters will be granted a 30-day option to purchase from the Company up to an additional 15% of the shares of its common stock. The Company intends to use the net proceeds received from its offering of common stock for working capital and general corporate purposes, including clinical trial and related expenses, research and development expenses, general and administrative expenses, and capital investments.

  • Business Wire

    Revance Announces Ground-Breaking Data Presentations at Leading International Neurotoxin Conference

    - Revance’s long-acting neuromodulator RT002, along with its unique proprietary peptide and formulation technology, will be featured in 11 podium and poster presentations at the TO

  • Business Wire

    Revance Highlights Recent Regulatory Progress and Provides Anticipated 2019 Milestones

    “Revance is entering 2019 with tremendous momentum on multiple fronts,” said Dan Browne, president and chief executive officer at Revance. “We have an exciting ensemble of late-stage clinical trials underway for our next-generation neuromodulator and are operating a U.S.-based, commercial-scale drug substance and drug product facility to manufacture a broad range of proprietary neuromodulation formulations.